NCT02345018

Brief Summary

The goal of this registry study is to provide insight in the safety and efficacy of treatment with MOCA for primary insufficiency of the GSV with a diameter \>/=12mm, insufficient antero-lateral branches and insufficiency of the GSV below the knee.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 19, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

January 26, 2015

Completed
1.3 years until next milestone

Study Start

First participant enrolled

June 1, 2016

Completed
5.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2022

Completed
Last Updated

April 27, 2022

Status Verified

April 1, 2022

Enrollment Period

5.8 years

First QC Date

January 19, 2015

Last Update Submit

April 26, 2022

Conditions

Keywords

Mechano-chemical ablationTreatment large varicose veinsBelow-knee and branchesEndovenous

Outcome Measures

Primary Outcomes (4)

  • Anatomical success

    Occlusion rate, evaluated using ultrasound scan

    4 weeks + 1 year

  • Clinical success

    CEAP, VCSS

    4 weeks + 1 year

  • Peroperative pain

    VAS-score

    Peroperative

  • Postoperative pain during 2 weeks post-treatment

    VAS-score, used pain medication

    During 2 weeks post-treatment

Secondary Outcomes (4)

  • Postoperative complications

    4 weeks + 1 year

  • Disease specific and general health status

    4 weeks + 1 year

  • Time to return to normal daily activities and work

    Post-treatment

  • Duration of the intervention using MOCA

    Peroperative

Study Arms (3)

GSV with diameters >/= 12 mm

30 patients with primary insufficiency of the GSV with diameters \>/= 12 mm, treated with mechano-chemical ablation (MOCA)

Procedure: Mechano-chemical ablation

Antero-lateral branches

30 patients with insufficient antero-lateral branches, treated with mechano-chemical ablation (MOCA)

Procedure: Mechano-chemical ablation

GSV below-knee

30 patients with below-knee GSV insufficiency, treated with mechano-chemical ablation (MOCA)

Procedure: Mechano-chemical ablation

Interventions

Treatment with mechano-chemical ablation

Also known as: MOCA
Antero-lateral branchesGSV below-kneeGSV with diameters >/= 12 mm

Eligibility Criteria

Age18 Years - 79 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with primary insufficiency of the GSV with diameters \>/=12 m m, insufficient antero-lateral branches or below-knee GSV insufficiency

You may qualify if:

  • Symptomatic varicose veins, C2-C5
  • Ultrasound criteria:
  • Diameter supragenual great saphenous vein (GSV) \>/= 12 mm , not tortuous; or
  • Insufficient antero-lateral branch; or
  • Insufficient below knee GSV
  • Signed informed consent
  • Patient consents to follow-up
  • Age \> 18 year en \< 80 year

You may not qualify if:

  • Patient is not capable to provide informed consent
  • Pregnancy and lactation
  • C6 varicose veins
  • Previous surgery or endovenous ablation at to treated segment
  • Deep venous vein thrombosis in medical history
  • Oral anti-coagulant therapy
  • Contra-indications or allergy for sclerosant
  • Immobilisation
  • Coagulant disorders or increased risk for thrombo-embolic complications: known coagulant disorders such as hemophilia A, hemophilia B, Von Willebrand disease, Glanzmann disease, factor VII-deficiency, idiopathic thrombo-cytopenic purpura, factor V Leiden disease and deep venous thrombosis or lung emboli in medical history
  • Fontaine III of IV peripheral arterial disease
  • Severe kidney disease: known GFR \< 30 ml/min
  • Liver diseases accompanied by changes in coagulation of the blood, anamnestic indications for tendency towards haemorrhage , such as epistaxis and spontaneous hematoma, known liver cirrhosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rijnstate Hospital

Arnhem, Gelderland, 6815 AD, Netherlands

Location

Related Publications (9)

  • Rasmussen LH, Bjoern L, Lawaetz M, Blemings A, Lawaetz B, Eklof B. Randomized trial comparing endovenous laser ablation of the great saphenous vein with high ligation and stripping in patients with varicose veins: short-term results. J Vasc Surg. 2007 Aug;46(2):308-15. doi: 10.1016/j.jvs.2007.03.053. Epub 2007 Jun 27.

    PMID: 17600655BACKGROUND
  • Helmy ElKaffas K, ElKashef O, ElBaz W. Great saphenous vein radiofrequency ablation versus standard stripping in the management of primary varicose veins-a randomized clinical trial. Angiology. 2011 Jan;62(1):49-54. doi: 10.1177/0003319710380680. Epub 2010 Aug 18.

    PMID: 20724299BACKGROUND
  • Subramonia S, Lees T. Randomized clinical trial of radiofrequency ablation or conventional high ligation and stripping for great saphenous varicose veins. Br J Surg. 2010 Mar;97(3):328-36. doi: 10.1002/bjs.6867.

    PMID: 20035541BACKGROUND
  • van Eekeren RR, Boersma D, Elias S, Holewijn S, Werson DA, de Vries JP, Reijnen MM. Endovenous mechanochemical ablation of great saphenous vein incompetence using the ClariVein device: a safety study. J Endovasc Ther. 2011 Jun;18(3):328-34. doi: 10.1583/11-3394.1.

    PMID: 21679070BACKGROUND
  • Boersma D, van Eekeren RR, Werson DA, van der Waal RI, Reijnen MM, de Vries JP. Mechanochemical endovenous ablation of small saphenous vein insufficiency using the ClariVein((R)) device: one-year results of a prospective series. Eur J Vasc Endovasc Surg. 2013 Mar;45(3):299-303. doi: 10.1016/j.ejvs.2012.12.004. Epub 2013 Jan 9.

    PMID: 23312507BACKGROUND
  • Bishawi M, Bernstein R, Boter M, Draughn D, Gould CF, Hamilton C, Koziarski J. Mechanochemical ablation in patients with chronic venous disease: a prospective multicenter report. Phlebology. 2014 Jul;29(6):397-400. doi: 10.1177/0268355513495830. Epub 2013 Jul 2.

    PMID: 23820117BACKGROUND
  • van Eekeren RR, Boersma D, Konijn V, de Vries JP, Reijnen MM. Postoperative pain and early quality of life after radiofrequency ablation and mechanochemical endovenous ablation of incompetent great saphenous veins. J Vasc Surg. 2013 Feb;57(2):445-50. doi: 10.1016/j.jvs.2012.07.049. Epub 2012 Nov 8.

    PMID: 23141679BACKGROUND
  • Timperman PE. Endovenous laser treatment of incompetent below-knee great saphenous veins. J Vasc Interv Radiol. 2007 Dec;18(12):1495-9. doi: 10.1016/j.jvir.2007.07.029.

    PMID: 18057283BACKGROUND
  • Theivacumar NS, Dellagrammaticas D, Mavor AI, Gough MJ. Endovenous laser ablation: does standard above-knee great saphenous vein ablation provide optimum results in patients with both above- and below-knee reflux? A randomized controlled trial. J Vasc Surg. 2008 Jul;48(1):173-8. doi: 10.1016/j.jvs.2008.01.062. Epub 2008 Apr 28.

    PMID: 18440756BACKGROUND

MeSH Terms

Conditions

Varicose Veins

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Officials

  • Michel Reijnen, MD, PhD

    Rijnstate Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Vascular surgeon

Study Record Dates

First Submitted

January 19, 2015

First Posted

January 26, 2015

Study Start

June 1, 2016

Primary Completion

April 1, 2022

Study Completion

April 1, 2022

Last Updated

April 27, 2022

Record last verified: 2022-04

Locations